Patient_Reported_Outcome_Measures_in_Rheumatic_Diseases

436

Table 18.2

The relation between MSUS- synovitis assessment and patient reported outcome measures in rheumatoid arthritis patients

at different disease

stages US parameter

PROMs parameter

Study

Number of patients

Disease duration (mean ± SD)

Signifi

cance

PD

≥

grade 2

Functional disability

• Gartner et al. [

60

]

-^90

• 9.4 ± 8.9 year
  -^

P -value: 0.019

• El Miedany et al. [

50

]

-^480

• 6.3 ± 2.1 month
  -^

P < 0.01

PD

≥

grade 2

Tender Joint count

• Cheung et al. [

67

]

-^50

• 15-years (median)

range: 10–21 year

• Positive LR (95 %

CI): 1.89 (1.52–2.35)

• El Miedany [

68

]

-^121

• 6.3 + 1.2 months
  -^

P < 0.01

PD

≥

grade 2

Swollen Joint count

• Cheung et al. [

67

]

-^50

• 15-years (median)


• Positive LR (95 %

CI): 2.54 (1.93–3.34)

Grayscale

≥

grade 2

Patient Global Assessment

• El Miedany et al. [

50

]

-^480

• 6.3 ± 201 month
  -^

P < 0.01

Pain Score Morning Stiffness

Grayscale

Adherence to therapy

• Joplin et al. [

82

]

-^18

• 49.2 ± 58.8 months
  -^

P < 0.01

J. Uson and Y. El Miedany